Clinical pharmacogenomics of warfarin and clopidogrel

Journal of Pharmacy Practice

Volumn 25, Issue 4, 2012, Pages 428-438

  Shin, Jaekyu ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

clopidogrel; pharmacogenomics; warfarin

Indexed keywords

AZATHIOPRINE; CLOPIDOGREL; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; FIBRINOGEN RECEPTOR ANTAGONIST; PRASUGREL; THIOPURINE METHYLTRANSFERASE; TICAGRELOR; TICLOPIDINE; TIOGUANINE; VITAMIN K GROUP; WARFARIN;

ALLELE; BLEEDING; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG ACTIVITY; DRUG CONTRAINDICATION; DRUG MEGADOSE; DRUG SCREENING; ETHNICITY; EVIDENCE BASED MEDICINE; GENE; GENE LOCUS; GENETIC POLYMORPHISM; GENOTYPE; HEART INFARCTION; HEREDITY; HUMAN; PATIENT CARE; PHARMACOGENOMICS; POINT OF CARE TESTING; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT RESPONSE; VKORC1 GENE;

EID: 84865263011     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190012448310     Document Type: Review

References (83)

1. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002 ; 287 (13). 1690-1698 (Pubitemid 34289221)
2. Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenomic data. N Engl J Med. 2009 ; 360 (8). 753-764
3. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005 ; 352 (22). 2285-2293 (Pubitemid 40740552)
4. Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenomic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008 ; 84 (3). 326-331
5. Princeton, NJ: ; 2010 :
6. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 ; 133 (6 suppl). 160S - 198S (Pubitemid 351892967)
7. The Human Cytochrome P450 (CYP) Allele Nomenclature Committee. 2008. http://www.cypalleles.ki.se/cyp2c9.htm. Accessed August 1, 2011.
8. Wei L, Locuson CW, Tracy TS. Polymorphic variants of CYP2C9: mechanisms involved in reduced catalytic activity. Mol Pharmacol. 2007 ; 72 (5). 1280-1288 (Pubitemid 350012601)
9. Lindh JD, Holm L, Andersson ML, et al. Influence of CYP2C9 genotype on warfarin dose requirements - a systematic review and meta-analysis. Eur J Clin Pharmacol. 2009 ; 65 (4). 365-375
10. Meckley LM, Wittkowsky AK, Rieder MJ, et al. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients. Thromb Haemost. 2008 ; 100 (2). 229-239
11. Palareti G, Legnani C, Guazzaloca G, et al. Risks factors for highly unstable response to oral anticoagulation: a case-control study. Br J Haematol. 2005 ; 129 (1). 72-78 (Pubitemid 40524054)
12. Voora D, Eby C, Linder MW, et al. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb Haemost. 2005 ; 93: 700-705 (Pubitemid 40485406)
13. Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med. 2005 ; 7 (2). 97-104 (Pubitemid 40261834)
14. Linder MW, Looney S, Adams JE, et al. Warfarin dose adjustments based on CYP2C9 genetic polymorphisms. J Thromb Thrombolysis. 2002 ; 14 (3). 227-232 (Pubitemid 37069306)
15. Wang D, Chen H, Momary KM, et al. Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood. 2008 ; 112: 1013-1021
16. Wadelius M, Chen LY, Downes K, et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 2005 ; 5 (4). 262-270 (Pubitemid 41131718)
17. Limdi NA, McGwin G, Goldstein JA, et al. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther. 2008 ; 83 (2). 312-321
18. Schwarz UI, Ritchie MD, Bradford Y, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med. 2008 ; 358 (10). 999-1008 (Pubitemid 351347099)
19. Anderson JL, Horne BD, Stevens SM, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation. 2007 ; 116 (22). 2563-2570 (Pubitemid 350179221)
20. Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005 ; 106 (7). 2329-2333 (Pubitemid 41510803)
21. Perini JA, Struchiner CJ, Silva-Assuncao E, et al. Pharmacogenomics of warfarin: development of a dosing algorithm for brazilian patients. Clin Pharmacol Ther. 2008 ; 84 (6). 722-728
22. Cavallari LH, Langaee TY, Momary KM, et al. Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin Pharmacol Ther. 2010 ; 87 (4). 459-464
23. Caldwell MD, Awad T, Johnson JA, et al. CYP4F2 genetic variant alters required warfarin dose. Blood. 2008 ; 111 (8). 4106-4112
24. Loebstein R, Dvoskin I, Halkin H, et al. A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood. 2007 ; 109 (6). 2477-2480 (Pubitemid 46425891)
25. Kadafour M, Haugh R, Posin M, et al. Survey on warfarin pharmacogenomic testing among anticoagulation providers. Pharmacogenomics. 2009 ; 10 (11). 1853-1860
26. Ginsburg GS, Voora D. The long and winding road to warfarin pharmacogenomic testing. J Am Coll Cardiol. 2010 ; 55 (25). 2813-2815
27. Meckley LM, Neumann PJ. Personalized medicine: factors influencing reimbursement. Health Policy. 2009 ; 94 (2). 91-100
28. Eckman MH, Rosand J, Greenberg SM, et al. Cost-effectiveness of using pharmacogenomic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med. 2009 ; 150 (2). 73-83
29. You JH, Tsui KK, Wong RS, et al. Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy. Clin Pharmacol Ther. 2009 ; 86 (5). 540-547
30. Meckley LM, Gudgeon JM, Anderson JL, et al. A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics. 2010 ; 28: 61-74
31. Genomic testing. Centers for Disease Control and Prevention, 2010. http://www.cdc.gov/genomics/gtesting/ACCE/. Accessed August 1, 2011.
32. Epstein RS, Moyer TP, Aubert RE, et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J Am Coll Cardiol. 2010 ; 55: 2804-2812
33. Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther. 2008 ; 83 (3). 460-470 (Pubitemid 351272635)
34. Huang SW, Chen HS, Wang XQ, et al. Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenet Genomics. 2009 ; 19 (3). 226-234
35. Burmester JK, Berg RL, Yale SH, et al. A randomized controlled trial of genotype-based Coumadin initiation. Genet Med. 2011 ; 13 (6). 509-518
36. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 ; 133 (6 suppl). 546S - 192S
37. Shin J, Cao D. Comparison of warfarin pharmacogenomic dosing algorithms in a racially diverse large cohort. Pharmacogenomics. 2011 ; 12: 125-134
38. Clinicaltrials.gov. National Institute of Health. http://clinicaltrials. gov/. Accessed August 1, 2011.
39. Thacker SM, Grice GR, Milligan PE, et al. Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? Yes. J Thromb Haemost. 2008 ; 6: 1445-1449
40. Lenzini P, Wadelius M, Kimmel S, et al. Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther. 2010 ; 87: 572-578
41. Finkelman BS, Gage BF, Johnson JA, et al. Genetic warfarin dosing: tables versus algorithms. J Am Coll Cardiol. 2011 ; 57 (5). 612-618
42. Shin J, Kayser SR. Accuracy of the pharmacogenomic dosing table in the warfarin label in predicting initial therapeutic warfarin doses in a large, racially diverse cohort. Pharmacotherapy. 2011 ;: 31
43. Schwartz JB, Kane L, Moore K, et al. Failure of pharmacogenomic-based dosing algorithms to identify older patients requiring low daily doses of warfarin. J Am Med Dir Assoc. 2011 ;:
44. Relling MV, Klein TE. CPIC: clinical pharmacogenomics implementation consortium of the pharmacogenomics research network. Clin Pharmacol Ther. 2011 ; 89: 464-467
45. Wright RS, Anderson JL. Adams CD, et al. 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011 ; 123: 2022-2060
46. Antman EM, Hand M. Armstrong PW, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2008 ; 51: 210-247
47. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007 ; 49: 1505-1516 (Pubitemid 46517957)
48. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009 ; 360: 363-375
49. Momary KM, Dorsch MP, Bates ER. Genetic causes of clopidogrel nonresponsiveness: which ones really count?. Pharmacotherapy. 2010 ; 30: 265-274
50. de Morais SM, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 1994 ; 269: 15419-15422
51. De Morais SM, Wilkinson GR, Blaisdell J, et al. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol. 1994 ; 46: 594-598 (Pubitemid 24334747)
52. Sim SC, Risinger C, Dahl ML, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006 ; 79: 103-113 (Pubitemid 43069582)
53. Combescure C, Fontana P, Mallouk N, et al. Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost. 2010 ; 8 (5). 923-933
54. 510(k) Premarket Notification. The US Food and Drug Administration. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm. Accessed August 1, 2011.
55. Varenhorst C, James S, Erlinge D, et al. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur Heart J. 2009 ; 30 (14). 1744-1752
56. Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA. 2010 ; 303 (8). 754-762
57. Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011 ; 305: 1097-1105
58. Gurbel PA, Becker RC, Mann KG, et al. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol. 2007 ; 50: 1822-1834 (Pubitemid 350007957)
59. Gurbel PA, Shuldiner AR, Bliden KP, et al. The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy. Am Heart J. 2011 ; 161: 598-604
60. Trenk D, Hochholzer W, Fromm MF, et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol. 2008 ; 51: 1925-1934 (Pubitemid 351636443)
61. Giusti B, Gori AM, Marcucci R, et al. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol. 2009 ; 103: 806-811
62. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009 ; 360: 354-62
63. Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J. 2009 ; 30: 916-922
64. Pare G, Mehta SR, Yusuf S, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med. 2010 ; 363: 1704-1714
65. Sorich MJ, Vitry A, Ward MB, et al. Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. J Thromb Haemost. 2010 ; 8: 1678-1684
66. Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010 ; 376: 1320-1328
67. Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation. 2010 ; 121: 512-518
68. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009 ; 373: 309-317
69. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009 ; 302: 849-857
70. Malek LA, Przyluski J, Spiewak M, et al. Cytochrome P450 2C19 polymorphism, suboptimal reperfusion and all-cause mortality in patients with acute myocardial infarction. Cardiology. 2010 ; 117: 81-87
71. Tiroch KA, Sibbing D, Koch W, et al. Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events. Am Heart J. 2010 ; 160: 506-512
72. Yamamoto K, Hokimoto S, Chitose T, et al. Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy. J Cardiol. 2011 ; 57: 194-201
73. Harmsze AM, van Werkum JW, Ten Berg JM, et al. CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. Eur Heart J. 2010 ; 31: 3046-3053
74. Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010 ; 304: 1821-1830
75. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted?. J Invasive Cardiol. 2004 ; 16: 169-174 (Pubitemid 38456448)
76. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes. 2005 ; 54 (8). 2430-2435 (Pubitemid 41134272)
77. Soffer D, Moussa I, Harjai KJ, et al. Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina?. Catheter Cardiovasc Interv. 2003 ; 59 (1). 21-25 (Pubitemid 36528793)
78. Barker CM, Murray SS, Teirstein PS, et al. Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity. JACC Cardiovasc Interv. 2010 ; 3: 1001-1007
79. Tantry US, Bliden KP, Wei C, et al. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. Circ Cardiovasc Genet. 2010 ; 3: 556-566
80. Maeda A, Ando H, Asai T, et al. Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine. Clin Pharmacol Ther. 2011 ; 89 (2). 229-233
81. Scott SA, Sangkuhl K, Gardner EE, et al. Clinical pharmacogenomics implementation consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther. 2011 ; 90 (2). 328-332
82. Effient [Package Insert]. Eli Lilly and Company, 2010. http://pi.lilly.com/us/effient.pdf. Accessed August 1, 2011.
83. Brilinta [Package Insert]. Astrazeneca, 2011. http://www1.astrazeneca-us. com/pi/brilinta.pdf. Accessed Ausgust 1, 2011.